Written by Jane Aubrey
BioVie has completed the last on-treatment visit in its ADDRESS-LC Phase 2 study of bezisterim for neurological symptoms associated with Long COVID. The August 31 announcement says the one-month virtual follow-up is nearly complete and that topline data are targeted before the end of September 2026. This is an operational milestone, not an efficacy result. The distinction is essential: the study is now positioned to report, but no clinical conclusion should be drawn until the prespecified data are released and interpreted.
ADDRESS-LC is a randomized, 1:1, placebo-controlled, multicenter proof-of-concept study enrolling approximately 200 adults with Long COVID who have cognitive-impairment sequelae and fatigue. It compares a 20 mg oral bezisterim capsule taken twice daily with matching placebo. The company says the endpoints include overall clinical benefit, subjective and objective cognitive function, fatigue, sleep disturbance, quality of life and post-exertional malaise. This is a broad symptom architecture, which reflects the heterogeneity of Long COVID but also raises the methodological importance of how endpoints are prioritized, measured and analyzed.
The study’s design includes features that make the eventual result more interpretable than an uncontrolled observation. Randomization balances known and unknown baseline differences across treatment groups; a placebo control helps separate a treatment signal from expectation effects and natural symptom fluctuation; and multicenter participation can improve generalizability. Yet a Phase 2 proof-of-concept study remains an early test. Even a positive result would need replication, careful safety assessment and a regulatory path before it could establish a new treatment standard.
BioVie describes bezisterim as an investigational oral drug that crosses the blood-brain barrier and aims to modulate inflammatory pathways and insulin sensitivity without immune suppression. It points to ERK, NFκB and TNF-alpha pathways as part of its biological rationale. The company also discusses a hypothesis that persistent inflammatory signaling may contribute to fatigue and cognitive symptoms in Long COVID. These are research hypotheses and proposed mechanisms, not proof that a specific biological process causes symptoms in every patient or that the investigational drug will produce a meaningful clinical benefit.
The funding structure is notable. BioVie says the study is fully supported by a $13.13 million award through the U.S. Department of War’s Peer-Reviewed Medical Research Program. External funding can reduce the direct financial burden of a mid-stage study, but it does not change the scientific standard for interpreting results. The company says the opinions and conclusions in the release are its own and not necessarily endorsed by the funding body. Readers should therefore distinguish grant support from validation of the therapy or its underlying hypothesis.
The forthcoming topline release should answer more than whether one symptom score moved. Key questions include which endpoints were met, the magnitude and consistency of any effect, the duration of benefit, discontinuations, adverse events, baseline characteristics and whether objective cognitive measures align with patient-reported outcomes. A statistically positive result with a small or inconsistent effect may have a different clinical meaning from a result that shows a coherent benefit across multiple measures. Conversely, a failed endpoint would not automatically resolve the broader biology of Long COVID; it would limit the evidence for this particular intervention and trial design.
Long COVID has a large unmet-need profile, but that is precisely why evidence discipline matters. ADDRESS-LC’s treatment completion brings the program closer to a genuine data event. Until the results arrive, bezisterim remains investigational and no approved therapy claim is warranted. This article is news analysis, not medical advice. Treatment decisions should be made with qualified clinicians using current evidence and regulatory information.
